Literature DB >> 34052541

Infections in activated PI3K delta syndrome (APDS).

Nina N Brodsky1, Carrie L Lucas2.   

Abstract

Activated PI3K-delta Syndrome (APDS), also called PI3K-delta activating mutation causing senescent T cells, lymphadenopathy, and immunodeficiency (PASLI), is an autosomal dominant disorder caused by inherited or de novo gain-of-function mutations in one of two genes encoding subunits of the phosphoinositide-3-kinase delta (PI3Kδ) complex. This largely leukocyte-restricted protein complex regulates cell growth, activation, proliferation, and survival. Patients who harbor these mutations have early onset immunodeficiency with recurrent infections, lymphadenopathy, and autoimmunity. The most common infection susceptibilities are sinopulmonary (encapsulated bacteria) and herpesviruses. Multiple defects in both innate and adaptive immune function are responsible for this phenotype. Apart from anti-microbial prophylaxis and immunoglobulin replacement, patients are treated with a variety of immunomodulatory agents and some have needed hematopoietic stem cell transplants. Here, we highlight the spectrum of infections, immune defects, and therapy options in this inborn error of immunity.
Copyright © 2021 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34052541     DOI: 10.1016/j.coi.2021.04.010

Source DB:  PubMed          Journal:  Curr Opin Immunol        ISSN: 0952-7915            Impact factor:   7.486


  3 in total

1.  Case Report: Successful Treatment With Monoclonal Antibodies in One APDS Patient With Prolonged SARS-CoV-2 Infection Not Responsive to Previous Lines of Treatment.

Authors:  Beatrice Rivalta; Donato Amodio; Carmela Giancotta; Veronica Santilli; Lucia Pacillo; Paola Zangari; Nicola Cotugno; Emma Concetta Manno; Andrea Finocchi; Stefania Bernardi; Luna Colagrossi; Leonarda Gentile; Cristina Russo; Carlo Federico Perno; Paolo Rossi; Caterina Cancrini; Paolo Palma
Journal:  Front Immunol       Date:  2022-06-21       Impact factor: 8.786

2.  Tailored therapies for primary immunodeficiencies.

Authors:  Bianca Cinicola; Federica Pulvirenti; Giulia Brindisi; Gian Luigi Marseglia; Riccardo Castagnoli; Thomas Foiadelli; Carlo Caffarelli; Amelia Licari; Michele Miraglia Del Giudice; Anna Maria Zicari; Marzia Duse; Fabio Cardinale
Journal:  Acta Biomed       Date:  2021-11-29

3.  Initial sirolimus dosage recommendations for pediatric patients with PIK3CD mutation-related immunodeficiency disease.

Authors:  Xiao Chen; Jinglin Wang; Jianger Lan; Xilin Ge; Hong Xu; Yu Zhang; Zhiping Li
Journal:  Front Pharmacol       Date:  2022-09-14       Impact factor: 5.988

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.